TY - JOUR
T1 - Phase I clinica trial of the use of zinc phthalocyanine tetrasulfonate as a photosensitizer for photodynamic therapy in dogs
AU - Borgatti-Jeffreys, Antonella
AU - Hooser, Stephen B.
AU - Miller, Margaret A.
AU - Lucroy, Michael D.
PY - 2007/4
Y1 - 2007/4
N2 - Objective - To determine the threshold for acute toxicosis of parenterally administered zinc phthalocyanine tetrasulfonate (ZnPcS4), a candidate second-generation photosensitizer, in mice and evaluate the compounds safety in a phase I clinical trial of ZnPcS4 photodynamic therapy (PDT) in pet dogs with naturally occurring tumors. Animals - Male Swiss-Webster mice and client-owned dogs with naturally occurring neoplasms. Procedures - For the study of acute toxicosis, mice were given graded doses of ZnPcS4. To determine safety, a rapid-titration phase I clinical trial of ZnPcS4-based PDT in tumor-bearing dogs was conducted. Results - In mice, administration of ≥ 100 mg of ZnPcS4/kg resulted in renal tubular necrosis 24 hours after IP injection. In tumor-bearing dogs, ZnPcS4 doses ≤ 4 mg/kg induced no signs of toxicosis and resulted in partial to complete tumor responses in 10 of 12 dogs 4 weeks after PDT. Tumor remission was observed with ZnPcS4 doses as low as 0.25 mg/kg. Conclusions and clinical relevance - A conservative starting dose of ZnPcS4 arrived at on the basis of mouse toxicosis findings. Zinc phthalocyanine tetrasulfonate-based PDT was tolerated well by all dogs and warrants further study. The identification of the maximum tolerated dose through traditional phase I clinical trials may be unnecessary for evaluating novel PDT protocols.
AB - Objective - To determine the threshold for acute toxicosis of parenterally administered zinc phthalocyanine tetrasulfonate (ZnPcS4), a candidate second-generation photosensitizer, in mice and evaluate the compounds safety in a phase I clinical trial of ZnPcS4 photodynamic therapy (PDT) in pet dogs with naturally occurring tumors. Animals - Male Swiss-Webster mice and client-owned dogs with naturally occurring neoplasms. Procedures - For the study of acute toxicosis, mice were given graded doses of ZnPcS4. To determine safety, a rapid-titration phase I clinical trial of ZnPcS4-based PDT in tumor-bearing dogs was conducted. Results - In mice, administration of ≥ 100 mg of ZnPcS4/kg resulted in renal tubular necrosis 24 hours after IP injection. In tumor-bearing dogs, ZnPcS4 doses ≤ 4 mg/kg induced no signs of toxicosis and resulted in partial to complete tumor responses in 10 of 12 dogs 4 weeks after PDT. Tumor remission was observed with ZnPcS4 doses as low as 0.25 mg/kg. Conclusions and clinical relevance - A conservative starting dose of ZnPcS4 arrived at on the basis of mouse toxicosis findings. Zinc phthalocyanine tetrasulfonate-based PDT was tolerated well by all dogs and warrants further study. The identification of the maximum tolerated dose through traditional phase I clinical trials may be unnecessary for evaluating novel PDT protocols.
UR - http://www.scopus.com/inward/record.url?scp=34247473871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247473871&partnerID=8YFLogxK
U2 - 10.2460/ajvr.68.4.399
DO - 10.2460/ajvr.68.4.399
M3 - Article
C2 - 17397295
AN - SCOPUS:34247473871
SN - 0002-9645
VL - 68
SP - 399
EP - 404
JO - American journal of veterinary research
JF - American journal of veterinary research
IS - 4
ER -